News

2015 Tribute Pharmaceuticals News Archive

Keyword Search
 
2015 | 2014 | 2013
DateTitle 
12/29/15RETRANSMISSION: Tribute Schedules Special Shareholder Meeting for February 1, 2016
MILTON, ONTARIO -- (Marketwired) -- 12/29/15 -- Tribute Pharmaceuticals Canada    Inc. (TSX VENTURE:TRX) (OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty    pharmaceutical company with a primary focus on the acquisition, licensing,    development and promotion of healthcare products in Canada and the U.S., today    announced that its special meeting of shareholders in connection with the pending    transaction with POZEN Inc. ("POZEN") (NA... 
Printer Friendly Version
12/28/15Tribute Schedules Special Shareholder Meeting for February 1, 2016
MILTON, ONTARIO -- (Marketwired) -- 12/28/15 -- Tribute Pharmaceuticals Canada    Inc. (TSX VENTURE:TRX) (OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty    pharmaceutical company with a primary focus on the acquisition, licensing,    development and promotion of healthcare products in Canada and the U.S., today    announced that its special meeting of shareholders in connection with the pending    transaction with POZEN Inc. ("POZEN") (NASDAQ:POZN) will be held on February 1, 2016    at ... 
Printer Friendly Version
12/07/15POZEN and Tribute Announce Plan to Proceed With Merger to Form Aralez Pharmaceuticals
-Canada Domicile Provides Similar Competitive    Structure and Benefits to Ireland-    -Previously Scheduled Shareholder Meetings of    POZEN and Tribute to be Rescheduled-    CHAPEL HILL, NORTH CAROLINA and MILTON, ONTARIO -- (Marketwired) -- 12/07/15 --    POZEN Inc. ("POZEN") (NASDAQ:POZN) and Tribute Pharmaceuticals Canada Inc.    ("Tribute") (TSX VENTURE:TRX)(OTCQX:TBUFF) today confirmed their merger plans and    announced that they have entered into an amended agreement and plan of merger,... 
Printer Friendly Version
11/09/15Tribute Announces Third Quarter 2015 Results
Revenue Up 133%, EBITDA Up 281% Over    Comparative Period    MILTON, ONTARIO -- (Marketwired) -- 11/09/15 -- Tribute Pharmaceuticals Canada    Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a diversified    healthcare company with a primary focus on the acquisition, licensing, development    and promotion of healthcare products in Canada and the U.S., today announced its    operational and financial results for the third quarter ended September 30, 2015.    Unless otherwise i... 
Printer Friendly Version
11/06/15POZEN and Tribute Announce Effectiveness of Registration Statement on Form S-4
POZEN Schedules Stockholder Meeting for December 10, 2015    Tribute Schedules Shareholder Meeting for December 9, 2015    CHAPEL HILL, N.C. & MILTON, Ontario--November 6, 2015--POZEN Inc. ("POZEN")    (POZN) and Tribute Pharmaceuticals Canada Inc. ("Tribute") (TRX.V) (TBUFF) today    announced that the registration statement on Form S-4 filed with the U.S. Securities    and Exchange Commission (SEC) by Aralez Pharmaceuticals Limited ("Aralez") on July    20, 2015, as amended on August 19, 2... 
Printer Friendly Version
09/29/15Tribute Comments on Trading Activity at the Request of IIROC
MILTON, ONTARIO -- (Marketwired) -- 09/29/15 -- Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced at the request of the Investment Industry Regulatory Organization of Canada ("IIROC"), that it is not aware of any reason for the recent decrease in... 
Printer Friendly Version
08/17/15Tribute Pharmaceuticals Announces Second Quarter 2015 Results
Revenue Up 59%, Gross Profit Up 101% over Comparative PeriodMILTON, ONTARIO -- (Marketwired) -- 08/17/15 -- Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced its operational and financial results for the second quarter ended June 30, 2015. Unless otherwise indicated, all dolla... 
Printer Friendly Version
06/17/15Tribute Pharmaceuticals Announces Acquisition of Medical Futures Inc., a Canadian Specialty Pharmaceutical Company
Includes Canadian Rights to Durela®, Proferrin® and 13 Additional ProductsMILTON, ONTARIO--(Marketwired - June 17, 2015) -NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., is pleased to announce that it ha... 
Printer Friendly Version
06/17/15Tribute Pharmaceuticals Announces Acquisition of Medical Futures Inc., a Canadian Specialty Pharmaceutical Company
Includes Canadian Rights to Durela(R), Proferrin(R) and 13 Additional ProductsMILTON, ONTARIO -- (Marketwired) -- 06/17/15 -- Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., is pleased to announce that it has acquired Medical Futures Inc. ("MFI") in a transaction valued at $25 million. Fin... 
Printer Friendly Version
06/08/15Pozen Announces Strategic Acquisition of Tribute and Growth Capital Commitment from Leading Healthcare Sponsors
Transformative Transaction Creates Premier Specialty Pharma Company Focused on Cardiovascular TreatmentsUS $350 Million Capital Commitment from Deerfield-Led Syndicate toFund Commercial Launch and Pursue Strategic Acquisitions and Growth OpportunitiesAdrian Adams Will Lead World-Class Management Team with Record of Growth and InnovationCHAPEL HILL, NC and MILTON, ON – June 8, 2015, POZEN Inc. (“POZEN”) (NASDAQ: POZN), a pharmaceutical company committed to developing medicine that transforms live... 
Printer Friendly Version
05/21/15Tribute Pharmaceuticals Announces Acquisition of U.S. Rights to Fibricor®, Commercial Expansion into U.S. Market and Completion of $12 Million Equity Financing
- William Maichle Hired as President of U.S. OperationsMILTON, ONTARIO--(Marketwired - May 21, 2015) -NOT FOR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICESTribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., is pleased to announce that its wholly owned subsidiary, Tribut... 
Printer Friendly Version
05/21/15Tribute Pharmaceuticals Announces Acquisition of U.S. Rights to Fibricor(R) and Commercial Expansion into U.S. Market
- William Maichle Hired as President of U.S. OperationsMILTON, ONTARIO -- (Marketwired) -- 05/21/15 -- Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., is pleased to announce that its wholly owned subsidiary, Tribute Pharmaceuticals International Inc., a Barbados corporation, has acquired t... 
Printer Friendly Version
05/12/15Tribute Pharmaceuticals Announces First Quarter 2015 Results
Revenue Up 60%, EBITDA Up 116% Over Comparative PeriodMILTON, ONTARIO -- (Marketwired) -- 05/12/15 -- Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced its operational and financial results for the first quarter ended March 31, 2015. Unless otherwise indicated, all dollar amo... 
Printer Friendly Version
05/08/15Tribute Pharmaceuticals Schedules First Quarter 2015 Financial Results Conference Call
MILTON, ONTARIO -- (Marketwired) -- 05/08/15 -- Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that it will host a conference call on Tuesday, May 12, 2015 at 9:00 AM EDT to review and discuss the Company's results for its first quarter ending March 31, 2015.To join the con... 
Printer Friendly Version
04/27/15Tribute Pharmaceuticals to Present at the Bloom Burton & Co. Annual Healthcare Investor Conference
MILTON, ONTARIO -- (Marketwired) -- 04/27/15 -- Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that Rob Harris, Chief Executive Officer, will present at the 2015 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Toronto Hotel on Monday, May 4, 201... 
Printer Friendly Version
04/15/15Tribute Pharmaceuticals Added to the S&P/TSX Venture Composite Index
MILTON, ONTARIO -- (Marketwired) -- 04/15/15 -- Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced, effective April 20, 2015, the Company will be added to the S&P/TSX Venture Select Index.The S&P/TSX Venture Select Index measures the combined performance of constituent... 
Printer Friendly Version
04/02/15Tribute Pharmaceuticals to Participate at Laurentian Bank Securities Annual Investor Conference
MILTON, ONTARIO -- (Marketwired) -- 04/02/15 -- Tribute Pharmaceuticals Canada Inc. ("Tribute" or the "Company") (TSX VENTURE:TRX) (OTCQX:TBUFF), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that Mr. Rob Harris, its President and Chief Executive Officer will participate in a Specialty Pharmaceutical Healthcare Panel Discussion to be held on Thursday, April 9, 2015 a... 
Printer Friendly Version
03/19/15Tribute Raises US$2.7 Million Through the Exercise of Warrants
MILTON, ONTARIO -- (Marketwired) -- 03/19/15 -- Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the United States, today announced that holders of 5,431,250 or 90.1% of the Series A Warrants issued in connection with the Company's 2013 unit financing were exercised prior to their expiry resulting in ... 
Printer Friendly Version
03/03/15Tribute Pharmaceuticals Announces Strong 2014 Fourth Quarter and Year End Results
4th Quarter Revenue Up 70.5% and EBITDA Up 217% Over Comparative PeriodsMILTON, ONTARIO -- (Marketwired) -- 03/03/15 -- Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced its operational and financial results for the fourth quarter and year ended December 31, 2014. Unless othe... 
Printer Friendly Version
03/02/15Tribute Pharmaceuticals Board Members and Management Exercise Series A Warrants
MILTON, ONTARIO -- (Marketwired) -- 03/02/15 -- Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF) (TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the United States, today announced that 100% of the participants in Tranche I of the Company's February/March 2013 private placement of units, which included a majority of the Company's officers and direc... 
Printer Friendly Version
02/26/15Tribute Pharmaceuticals Schedules Fourth Quarter and 2014 Year End Financial Results Conference Call
MILTON, ONTARIO -- (Marketwired) -- 02/26/15 -- Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that it will host a conference call on Tuesday, March 3, 2015 at 9 AM EDT to review and discuss the Company's results for its fourth quarter and year end December 31, 2014.To join... 
Printer Friendly Version
01/29/15Tribute Pharmaceuticals Engages BND Projects Inc. as Investor Relations Service Provider and Grants Options to Certain Officers and Directors
MILTON, ONTARIO -- (Marketwired) -- 01/29/15 -- Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US, today announced that it has retained BND Projects Inc. ("BND") to provide it with investor relations services. The services to be provided by BND include (i) introducing the Company to the Canadian... 
Printer Friendly Version
01/27/15Tribute Pharmaceuticals Provides Update of 2014 Revenues; Anticipates Fourth Quarter Revenue Growth in Excess of 60% and Full Year Revenue Growth of Greater Than 20%
MILTON, ONTARIO -- (Marketwired) -- 01/27/15 -- Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US, today provided an interim update on its anticipated fourth quarter performance and total fiscal 2014 performance as follows:Total revenues for the three month period ended December 31, 2014, are a... 
Printer Friendly Version
Data provided by Nasdaq. Minimum 15 minutes delayed.